Forward looking statements

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
### Heidelberg Pharma at a Glance

Developing new options to address major challenges in cancer therapy

#### Our Company
- Listed as Heidelberg Pharma AG
- Frankfurt Stock Exchange: HPHA
- Shares outstanding: 31.03 million
- Market cap: ~€130 million (30 June 2020)
- Headquarters: Ladenburg, Germany
- ~78 employees

#### Our Mission
- **Inhibition of RNA Polymerase II – new option in cancer therapy**
- **Overcome resistance mechanisms**
- **Kill dormant tumor cells**
- **High efficacy on aggressive TP53/17p deleted tumors**

#### Our Approach
- **Unique mode of action**
  - Induction of apoptosis by inhibition of RNA Polymerase II
  - Application of innovative payload by harnessing ADC therapeutic modality
- **Antibody Targeted Amanitin Conjugates (ATACs)**

**ATAC Technology**
Strategic Cornerstones

- Build proprietary ATAC pipeline
- Sign technology licensing collaborations
- Additional upside potential with partnered non-ATAC legacy clinical assets

Proprietary lead candidate HDP-101

Other proprietary ATAC candidates
GMP supply payload

Lead ATAC HDP-101
ATAC technology partnering
ATAC pipeline GMP supply
Partnered clinical assets

ATAC technology partnering with pharma and biotech
TLX250-CDx – imaging agent (REDECTANE®)
upamostat – uPA-serine protease inhibitor (MESUPRON®)
RedHill Biopharma (RoW), Link Health (China)

© Heidelberg Pharma AG
# ATACs – Growing Pipeline of Proprietary and Partnered Programs

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proprietary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple myeloma (DLBCL/CLL)</td>
<td></td>
<td></td>
<td></td>
<td>Proprietary</td>
</tr>
<tr>
<td>PSMA-ATAC</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td>Proprietary</td>
</tr>
<tr>
<td>CDXX-ATAC</td>
<td>CDXX</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
<td>Proprietary</td>
</tr>
<tr>
<td>CDXX-ATACs</td>
<td>CDXX</td>
<td>Solid / Hematological tumors</td>
<td></td>
<td></td>
<td></td>
<td>Proprietary Open for partnering</td>
</tr>
<tr>
<td><strong>ATAC technology partner</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGTA-117</td>
<td>CD117, CD45</td>
<td>HSCs, Conditioning programs for blood cancers and genetic diseases</td>
<td></td>
<td></td>
<td></td>
<td>Magenta</td>
</tr>
<tr>
<td>MGTA-XX-ATACs</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td>Takeda/Millennium</td>
</tr>
<tr>
<td>TAK-XX-ATACs</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td>JV Emergence</td>
</tr>
<tr>
<td>EMR-XX-ATAC</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Recent Key Achievements

Corporate Update & Proprietary ATAC Programs

Corporate Update
• €14.4 m raised from private placement
• US patent for diagnosis and treatment of patients with TP53/RNA polymerase II deletion
• European patent for amatoxin conjugates for tumor therapy
• Senior Medical Officer hired

Lead program HDP-101
• Preclinical toxicity testing – almost completed
• GMP production for trial supply

ATAC Technology Partnerships

- MGTA-117 chosen as the first ATAC candidate for clinical development
- Presentation of encouraging data for MGTA-117 and CD45-ATAC
- New collaborations with
  - Avrobio: conditioning for genetic diseases
  - Beam Therapeutics: conditioning for sickle cell anemia and beta thalassemia

Licensed Clinical Projects

- TLX250-CDx
  - Phase III trial recruiting in US, EU and Australia
  - Breakthrough therapy designation granted by FDA
- RHB-107
  - Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate MoA and potential activity against SARS-CoV-2 infection (COVID-19)
HDP-101 – Lead Proprietary ATAC Candidate
Strong Case for Multiple Myeloma

- Amanitin + Linker + BCMA antibody = HDP-101
- High chance and unmet medical need in multiple myeloma (MM) patients
  - BCMA expression highly restricted in MM, hematological tumor type = good accessibility to tumor cells
  - Current treatments: Chemotherapy, immunomodulatory drugs, proteasome inhibitors and autologous stem cell transplantation
  - MM remains incurable, median survival of ~30-60 months, 70,000 deaths p.a.
- Additional indications where BCMA expression highly restricted: Diffuse large B-cell lymphoma and chronic lymphocytic leukemia
- Biomarker approach for MM patients with TP53/RNA polymerase II (17p) deletion:
  - HDP-101 preferential activity against tumor cells with 17p chromosome deletion
  - Very high medical need for new treatment options
  - Provides opportunity for accelerated clinical development if preclinical data translate into clinical benefits

Company to apply for Fast Track designation for HDP-101 at time of IND submission
### HDP-101 – Current Development Activities

<table>
<thead>
<tr>
<th>Activity</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>GMP technology transfer to the contract manufacturer on an industrial scale</td>
<td>completed</td>
</tr>
<tr>
<td>Production of materials for the HDP-101-toxicology phase</td>
<td>completed</td>
</tr>
<tr>
<td>Preclinical studies with HDP-101-tox material</td>
<td>nearly completed</td>
</tr>
<tr>
<td>Longterm stability studies of HDP-101</td>
<td>ongoing</td>
</tr>
<tr>
<td>GMP production of HDP-101 to supply the planned clinical trial</td>
<td>nearly completed</td>
</tr>
<tr>
<td>Contact with study centers in the US and GER established</td>
<td>completed</td>
</tr>
<tr>
<td>Outline of the study design for the clinical trial</td>
<td>completed</td>
</tr>
<tr>
<td>Contracts with the study centers</td>
<td>In negotiation</td>
</tr>
<tr>
<td>Submission of the Investigational New Drug Application for the study</td>
<td>In preparation</td>
</tr>
<tr>
<td>Submission of the Clinical Trial Application for the study</td>
<td>In preparation</td>
</tr>
</tbody>
</table>

Approval of IND and CTA in the US and GER
Initiate study centers and enroll patients
Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for stem cell transplant with ATACs
Partner Magenta: Making Important Progress in ATAC Programs for Conditioning

**CD117**

- Magenta product candidate: MGTA-117
- Compelling preclinical data presented at several scientific and investor conferences
- New scientific collaborations with US companies
  - Avrobio: conditioning for genetic diseases
  - Beam Therapeutics: conditioning for sickle cell anemia and beta thalassemia
- Status of Magenta’s MGTA-117 activities
  - GMP manufacturing ongoing
  - Plan to complete IND-enabling studies and to enter clinical trials in 2021
  - Initial clinical data expected in 2021

**CD45**

- First data presented in Nov 2019 on use of targeted ADCs to reset immune system and halt progression of autoimmune disease
- Status:
  - GMP manufacturing started
  - Lead antibody identified and entered into IND-enabling studies
  - Plan to further advance candidate in 2020
Breakthrough therapy designation granted by FDA for non-invasive detection and staging of ccRCC which is still an unmet medical need

- ccRCC is the most common (85-95% of cases) and typically the most aggressive form of kidney cancer

- **ZIRCON**: A confirmatory, prospective, open-label, multi-center Phase III study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab (TLX250) to non-invasively detect ccRCC by PET/CT imaging in patients with indeterminate renal masses
  - Patient recruitment to be completed by end of 2020
  - Data to be expected 2021

- Market potential:
  - 129,000 RCC patients eligible for PET imaging with TLX250-CDx
  - Total Addressable Market (TAM) value:
    - US = USD275 m, EU = USD75 m

RHB-107 – S1 serine protease inhibitor

• Potential first-in-class small molecule targeting cancer, inflammatory lung diseases, and gastrointestinal diseases.

• Planned for further evaluation as the third arm in a Phase I/IIa combination study in advanced cholangiocarcinoma, subject to discussions with the FDA

• New scientific findings show that the mechanism of serine proteases also plays a role in COVID-19:
  • Anti-viral activity – Interferes with cleavage of viral receptors that enable attachment to host cells during infection
  • Supportive pre-clinical and clinical safety data in over 300 patients

• Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate MoA and potential activity against SARS-CoV-2 infection (COVID-19)

• Planning to initiate a Phase 2/3 study in mild to moderate COVID-19 outpatients at the end of 2020
### Profit and Loss H1 2020

<table>
<thead>
<tr>
<th></th>
<th>H1 2020*</th>
<th>H1 2019*</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Earnings</strong></td>
<td>3.8</td>
<td>4.1</td>
<td>-8%</td>
</tr>
<tr>
<td><strong>Sales revenue</strong></td>
<td>3.1</td>
<td>3.8</td>
<td>-17%</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td>0.7</td>
<td>0.3</td>
<td>81%</td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td>13.2</td>
<td>8.4</td>
<td>56%</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>2.6</td>
<td>1.9</td>
<td>33%</td>
</tr>
<tr>
<td><strong>R&amp;D costs</strong></td>
<td>8.7</td>
<td>5.0</td>
<td>75%</td>
</tr>
<tr>
<td><strong>Administrative costs</strong></td>
<td>1.7</td>
<td>1.4</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td>0.2</td>
<td>0.1</td>
<td>154%</td>
</tr>
<tr>
<td><strong>Net loss for the period</strong></td>
<td>-9.4</td>
<td>-4.3</td>
<td>118%</td>
</tr>
</tbody>
</table>

* Fiscal year starts December 1\(^{st}\); first half ends May 31\(^{st}\)

- R&D significantly higher due to
  - cost-intensive external GMP production
  - preclinical and regulatory preparations for the clinical trial with HDP-101
<table>
<thead>
<tr>
<th>Assets (€ m)</th>
<th>31.05.2020</th>
<th>30.11.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>12.1</td>
<td>11.4</td>
</tr>
<tr>
<td>Other current assets</td>
<td>1.9</td>
<td>1.7</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>15.1</td>
<td>9.9</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>29.1</strong></td>
<td><strong>23.0</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity and Liabilities (€ m)</th>
<th>31.05.2020</th>
<th>30.11.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current liabilities</td>
<td>7.4</td>
<td>6.5</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Equity</td>
<td>21.5</td>
<td>16.3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>29.1</strong></td>
<td><strong>23.0</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cash Flow (€ m)</th>
<th>H1 2020</th>
<th>H1 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash as of 1 December 2019 / 1 December 2018</td>
<td>9.9</td>
<td>19.4</td>
</tr>
<tr>
<td>Net change in cash from operating activities</td>
<td>-8.3</td>
<td>-5.7</td>
</tr>
<tr>
<td>Net change in cash from investing activities</td>
<td>-0.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>Net change in cash from financing activities</td>
<td>14.3</td>
<td>0</td>
</tr>
<tr>
<td>Cash as of 31 May 2020 / 31 May 2019</td>
<td>15.1</td>
<td>13.1</td>
</tr>
</tbody>
</table>

- Total assets increased mainly due to the capital increase in April 2020
- Cash and cash equivalents of €15.1 million as of 31 May 2020 (30 November 2019: €9.9 million)
- Average monthly funding requirement was €1.5 million (previous year: €1.1 million)
Heidelberg Pharma Shares

Share performance 2020 ytd

- High: €9.300 (19 March 2020)
- Low: €2.060 (2 January 2020)
- Avg. daily trading volume: 49,221 shares (2019: 9,095)
- Shares outstanding: 31,030,572 (as of 30 June 2020)
- Current market cap: ~€130 m

Update

- New ticker: HPHA
- Solebury Trout for US IR activities hired
- MainFirst new designated sponsor/market maker

Share ownership as of 30 June 2020

- Corporate bodies * 1%
- Freefloat 19%
- UCB 3%
- Dietmar Hopp and affiliated companies** 77%

* held directly
** dievini Hopp BioTech holding GmbH & Co. KG + DH Holding Verwaltungs GmbH

Analyst coverage

- MainFirst 06/20: target €6.30
- EQUI.TS 04/20: target €6.15
- Pareto 04/20: target €4.20
Financials

<table>
<thead>
<tr>
<th>in € m</th>
<th>FY 2019</th>
<th>6M 2020</th>
<th>Guidance 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>8.0</td>
<td>3.8</td>
<td>8.0 to 10.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>18.1</td>
<td>13.2</td>
<td>20.0 to 24.0</td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>-10.1</td>
<td>-9.4</td>
<td>-11.0 to -15.0</td>
</tr>
<tr>
<td>Funds required</td>
<td>9.6</td>
<td>9.0</td>
<td>11.0 to 15.0</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>0.8</td>
<td>1.5</td>
<td>0.9 to 1.3</td>
</tr>
</tbody>
</table>

- Guidance for 2020 confirmed
- 6M figures in line with guidance, significant increase in operating expenses due to cost-intensive external GMP production and preparation for start of clinical development
- Sufficient funds for operational activities until at least mid-2021 based on current planning
Next Steps and Potential Milestones

ATAC technology and proprietary pipeline

**HDP-101 – plan for next steps**
- Complete GLP toxicity study (July 2020)
- GMP manufacturing of clinical trial material (July 2020)
- FDA pre-IND Meeting (Q3 2020)
- Submit Investigational New Drug Application in US (Q3/Q4 2020)
- Submit Clinical Trial Application in Germany (Q4 2020)
- Site activation und first patient in (Q1 2021)
- Continue biomarker development

**Select next proprietary development candidate**

**Magenta collaboration**
- Start MGTA-117 clinical development program

**Sign additional license and collaboration agreements**

Partnered legacy clinical programs

**TLX250-CDx®— imaging agent**
- Telix: ZIRCON Phase III trial: completion of patient recruitment planned by end of 2020
- Rolling BLA process to start

**TLX250 - ^{177}Lu-DOTA-girentuximab**
- Telix: Initiate trials with therapeutic radio-immuno-conjugate & checkpoint inhibitor in the US

**RHB-107 – serine protease inhibitor**
- RedHill: Preparations for Phase 2/3 clinical development program with RHB-107 for COVID-19
Investment Summary

Developing new options to address major challenges in cancer therapy

• **Disruptive first-in-humans** mode of action provides **high efficacy** and **potential for unique clinical advantages**, including treatment of dormant tumor cells

• **Increased efficacy against 17p deleted and aggressive** tumor cells based on **biomarker**

• Validated by **high quality collaborations** (early validation and cash)

• **High value potential** with growing proprietary portfolio
## Upcoming Conferences and Events

<table>
<thead>
<tr>
<th>Upcoming conferences &amp; events</th>
<th>Venue</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEGS: The Essential Protein Engineering &amp; Cell Therapy Summit</td>
<td>Delivered digitally</td>
<td>31 Aug – 04 Sept 2020</td>
</tr>
<tr>
<td>International HealthTech Innovation Days</td>
<td>Paris</td>
<td>05 – 06 October 2020</td>
</tr>
<tr>
<td>BioCapital Europe</td>
<td>Amsterdam</td>
<td>07 October 2020</td>
</tr>
<tr>
<td>BIO-Europe</td>
<td>Delivered digitally</td>
<td>26 – 29 October 2020</td>
</tr>
<tr>
<td>German Equity Forum</td>
<td>Delivered digitally</td>
<td>16 – 18 November 2020</td>
</tr>
<tr>
<td>World ADC Asia</td>
<td>Tokyo</td>
<td>07 – 09 December 2020</td>
</tr>
</tbody>
</table>

## Financial Calendar

<table>
<thead>
<tr>
<th>Financial Calendar</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virtual Annual General Meeting</td>
<td>22 July 2020</td>
</tr>
<tr>
<td>Q3 – Interim Results</td>
<td>08 October 2020</td>
</tr>
</tbody>
</table>

---

### Heidelberg Pharma AG

Schriesheimer Strasse 101  
68526 Ladenburg, Germany  
Tel.: +49 6203 1009-0  
Fax: +49 6203 1009-19  
Website: www.heidelberg-pharma.com

### IR/PR support

MC Services AG  
Katja Arnold (CIRO)  
Tel.: +49 89 210 288-40  
Email: katja.arnold[at]mc-services.eu

### Ticker data

<table>
<thead>
<tr>
<th>ISIN:</th>
<th>DE000A11QVV0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol:</td>
<td>HPHA</td>
</tr>
<tr>
<td>Reuters:</td>
<td>HPHA.DE</td>
</tr>
<tr>
<td>Bloomberg:</td>
<td>HPHA.GY</td>
</tr>
</tbody>
</table>